Physician

Matthew Christopher Konerman, M.D.

According to 2025 Medicare claims, Matthew Konerman, M.D. (NPI: 1659557247) practices advanced heart failure and transplant cardiology in the Ann Arbor, MI market, with the plurality of this provider's patient population coming from Washtenaw, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1891205969; TIN: 386006309) and primary practice location at 48109-5000. Konerman is affiliated with the POM ACO (ACO ID: A1297) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Konerman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 242 traditional Medicare patients, billed 388 HCPCS/CPT codes, and received $23,007 in Medicare payments. The top billing code was 99221 (Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes). Part D data shows 3,590 prescription claims across 410 beneficiaries totaling $2,436,140 in drug costs, led by Vyndamax (Tafamidis). DME data shows 30 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $23,977 to $23,007. In contrast, Part D prescription costs have moved sharply higher in recent years, from $8,869 to $2,436,140. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $9,457 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	103	338	$23,977
2017	252	846	$72,523
2018	296	856	$79,048
2019	315	863	$71,263
2020	272	815	$63,436
2021	291	631	$49,185
2022	325	743	$66,256
2023	219	412	$28,678
2024	242	388	$23,007

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	36	115	$8,869
2016	62	276	$15,172
2017	131	925	$75,333
2018	179	1,529	$131,379
2019	208	1,666	$216,968
2020	230	2,064	$873,794
2021	288	2,426	$988,284
2022	358	2,951	$1,274,898
2023	366	3,264	$1,540,453
2024	410	3,590	$2,436,140

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	50	$6,168
2019	N/R	22	$479
2020	N/R	73	$3,715
2021	N/R	69	$2,626
2022	N/R	29	$460
2023	N/R	51	$1,047
2024	N/R	30	$697

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99221	Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes	17	17	$67
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	36	37	$66
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	83	87	$44
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	39	48	$39
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	56	58	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	47	1,410	$1,019,662
Vyndaqel	Tafamidis Meglumine	20	660	$467,447
Jardiance	Empagliflozin	175	12,549	$236,112
Eliquis	Apixaban	196	11,749	$220,046
Entresto	Sacubitril/Valsartan	123	9,110	$193,142

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	17	$472
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$226

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Matthew Christopher Konerman, M.D.?

Tedicare shows public-source Medicare data for Matthew Christopher Konerman, M.D. (NPI 1659557247), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Christopher Konerman, M.D. have ACO affiliation data?

Matthew Christopher Konerman, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Matthew Christopher Konerman, M.D.?

Matthew Christopher Konerman, M.D. is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1891205969) in the available physician profile data.

Does Matthew Christopher Konerman, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.